Cargando…
培美曲塞治疗全身化疗和吉非替尼治疗失败的肺腺癌32例临床观察
BACKGROUND AND OBJECTIVE: The relapse-free time of gefitinib as the second or third line therapy in patients with advanced non-small cell lung cancer (NSCLC) was not satisfactory. The aim of this study is to evaluate the efficacy and toxicity of pemetrexed in patients with pulmonary adenocarcinoma a...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
中国肺癌杂志编辑部
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000551/ https://www.ncbi.nlm.nih.gov/pubmed/20704823 http://dx.doi.org/10.3779/j.issn.1009-3419.2010.08.11 |
Ejemplares similares
-
培美曲塞在晚期非小细胞肺癌二线及以上治疗中的疗效分析
Publicado: (2012) -
吉非替尼治疗32例肺腺癌脑转移的临床经验
Publicado: (2015) -
盐酸埃克替尼一线治疗晚期肺腺癌的临床疗效观察
Publicado: (2013) -
吉非替尼对比培美曲塞二线治疗晚期非鳞型非小细胞肺癌的随机对照临床研究
Publicado: (2013) -
培美曲塞联合顺铂或卡铂治疗复发或转移性非小细胞肺癌63例疗效分析
Publicado: (2011)